Author/Authors :
Zarrabi, Zeynab Departments of Medicinal Chemistry and Isfahan Pharmaceutical Research Center - School of Pharmacy and Pharmaceutical Sciences and Mycology and Parasitology - School of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran , Saghaie, Lotfollah Departments of Medicinal Chemistry and Isfahan Pharmaceutical Research Center - School of Pharmacy and Pharmaceutical Sciences and Mycology and Parasitology - School of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran , Fassihi, Afshin Departments of Medicinal Chemistry and Isfahan Pharmaceutical Research Center - School of Pharmacy and Pharmaceutical Sciences and Mycology and Parasitology - School of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran , Pestechian, Nader Departments of Medicinal Chemistry and Isfahan Pharmaceutical Research Center - School of Pharmacy and Pharmaceutical Sciences and Mycology and Parasitology - School of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran , Saberi, Sedigheh Departments of Medicinal Chemistry and Isfahan Pharmaceutical Research Center - School of Pharmacy and Pharmaceutical Sciences and Mycology and Parasitology - School of Medicine - Isfahan University of Medical Sciences, Isfahan, Iran
Abstract :
Background: Leishmaniasis infection threatens millions of people in under developing and developing
countries. Treatment of this neglected disease is very complicated. Subjects and Methods: A novel
series of antimony (V) complexes using bidentate ligands of hydroxypyranones and hydroxypyridinones
have been designed and synthesized. For the synthesis of the complexes, SbCl5 in water was added to
the solution of each ligand at 60°C and the pH of mixture was adjusted to 8 using aqueous NaOH. After
24 h stirring, extraction of produced compound into acetone gave the desired complex. The structure
of complexes was achieved by using FTIR, 1HNMR, and electron spin ionization mass spectroscopic
techniques. All compounds were evaluated for in vitro anti amastogote form of Leishmania major.
Results and Conclusion: The most potent antimony complexes against amastigotes were 5b (after 48
and 72 h) and 5a (after 72 h) with IC50 values of 24.4, 16.3, and 30.1 μg/mL, respectively. Furthermore,
antimony and iron complexes were used together for in vitro anti amastigote form of L. major activity.
These compounds were toxic for macrophages and destroyed them.
Keywords :
Anti-leishmania activity , antimony (V) complexes , iron complexes , Leishmania major